2016-07-25 19:59:16 UTC

What Happens to Infants Whose Mothers Took Anti-TNF Agents During Pregnancy?

July 25, 2016

Gastro study says anti-TNF agents can be detected in infants born to mothers with IBD who took the drugs during pregnancy.

Anti-tumor necrosis factor (TNF) agents can be detected in infants born to mothers with inflammatory bowel diseases (IBD) who took the drugs during pregnancy, researchers report in the July issue of Gastroenterology. Infliximab is cleared more slowly than adalimumab from infants. However, measurable levels in infants do not seem to be of significant clinical consequence, researchers say.

Women of reproductive age with IBD face the challenge of being healthy enough to conceive and carry a successful pregnancy, while also having to protect the fetus from the potential adverse effects of drugs needed to maintain remission.

To read more about this study and its findings, head to the AGA Journals Blog for a comprehensive study overview.

More on Crohn's Disease

Crohn's & Colitis Congress™ (A Partnership of the Crohn's & Colitis Foundation and American Gastroenterological Association)

Feb. 7, 2019

Expand your knowledge, network with IBD leaders, spark innovative research and get inspired to improve patient care.

Principles of GI for the NP and PA

Aug. 10, 2018

Hear from the experts as they provide you with critical updates on treating and managing patients with a variety of GI disorders.

Best Practices in IBD: Differential Diagnosis

March 15, 2018

This activity outlines the different pathophysiologic processes and symptoms that differentiate IBD and from functional bowel disorders such as IBS, and it reviews AGA’s Crohn's disease and ulcerative colitis “Clinical Care Pathways.”